

Cardioquin advertisement.


[s.l.]: [s.n.], 1970

https://digital.library.wisc.edu/1711.dl/YJ5CSA2OD2LSX8B

http://rightsstatements.org/vocab/InC/1.0/

The libraries provide public access to a wide range of material, including online exhibits, digitized collections, archival finding aids, our catalog, online articles, and a growing range of materials in many media.

When possible, we provide rights information in catalog records, finding aids, and other metadata that accompanies collections or items. However, it is always the user's obligation to evaluate copyright and rights issues in light of their own use.



convert to and maintain normal sinus rhythm

CARDIOQUIN TABLETS QUINIDINE POLYGALACTURONATE

- A better-tolerated quinidine molecule—lower incidence of local G.I. irritation than with quinidine sulfate
- Many patients, unable to tolerate quinidine sulfate, may be converted to normal sinus rhythm with quinidine polygalacturonate
- Indicated for both conversion and maintenance
- Flexible dosage permits the physician to retain control of conversion by dosage adjustment when necessary

BRIEF SUMMARY-INDICATIONS: Prevention and termination of atrial fibrillation, atrial flutter, atrial premature contractions, paroxysmal atrial tachycardia, paroxysmal ventricular tachycardia, premature ventricular contractions. CONTRAINDICATIONS: 1) Absolute: Complete atrioventricular heart block or history of previous sensitivity reactions. 2) Relative: Partial a-v and bundle branch block, severe cardiac failure and hypertrophy, chronic valvular disease, subacute bacterial endocarditis, acute infection, advanced age. PRECAUTIONS: The same as with all quinidine salts. Frequent ECG recommended; discontinue drug if ECG shows conduction system defects. Decrease dosage if signs of cinchonism develop. Initial therapeutic dose should be used as test dose for possible hypersensitivity. COMPOSITION: Each CARDIOQUIN Tablet (quinidine polygalacturonate 275 mg.) is equivalent in quinidine content to 3 grains quinidine sulfate. DOSAGE AND ADMINISTRATION: See PDR, p. 997. Detailed information and references available to physicians on request.

Purdue Frederick The Purdue Frederick Company, Yonkers, New York 10701